MITHRL RAISES $20M FOR BIOPHARMA AI PLATFORM

Mithrl's platform combines a custom-built biomedical world model with existing pharmaceutical company workflows. The technology targets a critical bottleneck in drug discovery: accelerating the computational analysis and hypothesis generation phases of research and development. Obvious Ventures led the round, with CEO Vivek Adarsh confirming the funding in an exclusive statement. The $20 million brings increased capital to an emerging class of AI tools designed specifically for life sciences applications. The biopharma sector has become a focal point for AI investment as companies seek to compress development timelines and reduce R&D costs. Mithrl positions itself as infrastructure rather than a standalone application, allowing pharmaceutical firms to integrate AI directly into established workflows rather than adopting entirely new systems. The company joins a growing cohort of AI startups targeting drug discovery and development, competing alongside platforms focused on protein folding, molecular simulation, and clinical trial optimization.